Theralase Technologies Inc (TLTFF)

[123414]

Let's talk Dec 2nd buying. TLTFF action consisted of 626,028 shares sold that day with 408,197 shorted. Dec 2nd opened at .2066 and closed at .2592. I think the principal buying came from let's say Data aware private investors, who expect in the near term the stock price will rise. So they wanted to get them shares.

Let's talk Dec 3. TLTFF action consisted of 1,038,430 shares sold that day with 594,900 shorted. Dec 3rd opened at .27 and closed at .2793. I think both days saw them strip out TLTFF stock from brokers and brokers had to refill. I think also Data aware private investors were looking to maybe burn hostile shorts.

Theralase has many irons in the fire. They are heads down getting the work done. I do think the bargains on this stock are over. I enjoyed some good buying with the covid delay. And some more good buying on the somewhat bumpy start. I bought some this week and will continue to buy. Theralase is working towards a covid vaccine since April. The Canadian government is all up in there with them because they see the data.

We are moving solidly towards a very cold flu season.

-------------------------------------------------

In April 2021, Theralase executed a Collaborative Research Agreement with the National Microbiology Laboratory, Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Under the terms of the agreement, Theralase and PHAC are collaborating on the development and optimization of a COVID-19 vaccine. The project is entitled, Dynamic Compound Inactivation of SARS-CoV-2 Vaccine and commenced in mid-April 2021. This research and development is currently ongoing and no reportable data is available at this time.

https://theralase.com/wp-content/uploads/2021/11/3Q-2021-Newsletter.pdf